deamino-arginine-vasopressin and Peritonitis

Topics: Antibodies, Monoclonal, Murine-Derived; Antifibrinolytic Agents; Appendicitis; B-Lymphocytes; Blood Loss, Surgical; Child; Deamino Arginine Vasopressin; Factor VIIa; Factor VIII; Hemophilia A; Humans; Immunosuppressive Agents; Infusions, Intravenous; Isoantibodies; Lymphocyte Count; Male; Mutation, Missense; Peritonitis; Postoperative Hemorrhage; Recombinant Proteins; Rituximab

An enzyme immuno assay was developed to measure complexes of tissue-type plasminogen activator (t-PA) with C1-inhibitor in order to study the role of C1-inhibitor as an inhibitor of t-PA in plasma. In vitro experiments with melanoma and recombinant t-PA learned that purified C1-inhibitor reacts with both single chain t-PA and two chain t-PA. The rate constants ranged from 3.0 to 5.2 M-1s-1. In plasma, melanoma and recombinant two chain t-PA were hardly inhibited by C1-inhibitor, in contrast to melanoma and recombinant single chain t-PA which were inhibited to the same extent by endogenous C1-inhibitor as they were by purified C1-inhibitor. In vivo, t-PA/C1-inhibitor complex could be measured in plasma in a few cases in healthy volunteers (0.62 +/- 0.43 ng/ml t-PA equivalents), after exercise (0.84 +/- 0.25 ng/ml t-PA equivalents) and after a desmopression infusion (0.26 +/- 0.04 ng/ml t-PA equivalents). However, t-PA/C1-inhibitor complex was found in plasma in all cases after venous occlusion (1.7 +/- 0.5 ng/ml t-PA equivalents), in peritoneal fluid from patients suffering from peritoneal inflammatory disease (2.2 +/- 1.3 ng/ml t-PA equivalents) and in plasma from healthy volunteers during a t-PA infusion (27.7 +/- 18.5 ng/ml t-PA equivalents at peak level). In the last case, about 8% of the infused dose of recombinant t-PA (alteplase) was inhibited by C1-inhibitor at peak level.(ABSTRACT TRUNCATED AT 250 WORDS)

Topics: Complement C1 Inactivator Proteins; Constriction; Deamino Arginine Vasopressin; Enzyme-Linked Immunosorbent Assay; Half-Life; Humans; Melanoma; Neoplasm Proteins; Peritonitis; Recombinant Proteins; Reproducibility of Results; Sensitivity and Specificity; Tissue Plasminogen Activator; Tumor Cells, Cultured; Urokinase-Type Plasminogen Activator; Veins